香港股市 已收市
  • 恒指

    21,958.36
    -113.82 (-0.52%)
     
  • 國指

    7,505.79
    -54.61 (-0.72%)
     
  • 上證綜指

    3,285.67
    +0.75 (+0.02%)
     
  • 道指

    33,825.32
    -267.64 (-0.79%)
     
  • 標普 500

    4,149.39
    +30.18 (+0.73%)
     
  • 納指

    12,073.28
    +256.96 (+2.17%)
     
  • Vix指數

    17.46
    -1.94 (-10.00%)
     
  • 富時100

    7,834.73
    +73.62 (+0.95%)
     
  • 紐約期油

    76.47
    +0.06 (+0.08%)
     
  • 金價

    1,958.80
    +16.00 (+0.82%)
     
  • 美元

    7.8422
    +0.0021 (+0.03%)
     
  • 人民幣

    0.8569
    -0.0022 (-0.26%)
     
  • 日圓

    0.0609
    +0.0004 (+0.61%)
     
  • 歐元

    8.5609
    -0.0519 (-0.60%)
     
  • Bitcoin

    23,857.56
    +780.99 (+3.38%)
     
  • CMC Crypto 200

    545.40
    +0.08 (+0.02%)
     

Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate

Zymergen Inc (NASDAQ: ZY) announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets.

  • Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow.

  • The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for all three target pathogens.

  • For PfAPP, Zymergen has already identified over 200 molecules with better docking scores than the current molecule, apstatin.

  • Docking scores are well-accepted in the industry for virtual screening campaigns, and the best hits are now being moved into validation testing with global partners.

  • Zymergen will oversee all validation.

  • Price Action: ZY shares closed 0.62% higher at $3.25 during after-hours trading on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.